NDA 050606 · Ani Pharms
Vancocin Hydrochloride
Vancomycin Hydrochloride · Oral
Last checked: Nov 19, 2026Latest source record: Dec 22, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1986
Apr 15, 1986
Approved uses
3
Original approval plus efficacy supplements
Registered trials
501
123 Phase 3, 64 recruiting
FAERS reports
8,212
7,409 serious, 1,633 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 2, 2026.
Vancomycin Hydrochloride Capsules are indicated for the treatment of Clostridioides difficile -associated diarrhea. Vancomycin Hydrochloride Capsules are also used for the treatment of enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains) in adult and pediatric patients less than 18 years of age. Limitations of Use • Parenteral administration of vancomycin is not effective for the above infections; therefore, Vancomycin Hydrochloride Capsules must be given orally for these infections. • Orally administered Vancomycin Hydrochloride Capsules are not effective for other types of infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Vancomycin Hydrochloride Capsules and other antibacterial drugs, Vancomycin Hydrochloride Capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Vancomycin Hydrochloride Capsules are a glycopeptide antibacterial indicated in adult and pediatric patients (less than 18 years of age) for the treatment of: ( 1 ) • Clostridioides difficile-associated diarrhea • Enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains) Limitations of Use: ( 1 ) ( 5.1 ) • Parenteral administration of vancomycin is not effective for the above infections; therefore, Vancomycin Hydrochloride Capsules must be given orally for these infections. • Orally administered Vancomycin Hydrochloride Capsules are not effective for other...
Mechanism: Vancomycin is an antibacterial drug [see Microbiology ( 12.4 )] .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 14, 2011 Supplement 28 · Efficacy LabelLetter
- Mar 17, 2004 Original approval · Supplement
- Apr 15, 1986 Original approval · Type 3 - New Dosage Form
2 products under this application
- VANCOCIN HYDROCHLORIDE · VANCOMYCIN HYDROCHLORIDE EQ 250MG BASE · CAPSULE, ORAL · Prescription · TE AB
- VANCOCIN HYDROCHLORIDE · VANCOMYCIN HYDROCHLORIDE EQ 125MG BASE · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Vancomycin" as an intervention, any sponsor and status, largest first.
- Prevention of Infections in Cardiac Surgery (PICS): a Cluster-randomized Factorial Cross-over TrialPivotal-lookingNot yet recruiting
Hamilton Health Sciences CorporationAcademic, hospital or other
NCT06567808 · 38,000 participants (planned) · Start Mar 1, 2026 · Primary completion Apr 30, 2028
Drug: Cefazolin; Vancomycin · For: Infection, Surgical Site
VA Office of Research and DevelopmentFederal agency
NCT02216227 · 23,005 participants · Start Apr 1, 2014 · Primary completion Feb 28, 2021
Drug: Mupirocin; Chlorhexidine gluconate and 3 more · For: Surgical Site Infection
Sites: Miami, Florida; Iowa City, Iowa; Baltimore, Maryland · 11 sites in all
- Infection Prophylaxis in Total Joint ReplacementPivotal-lookingRecruiting
Hamilton Health Sciences CorporationAcademic, hospital or other
NCT06126614 · 21,006 participants (planned) · Start May 7, 2024 · Primary completion Nov 2028
Drug: Chlorhexidine Gluconate; Vancomycin Hydrochloride · For: Periprosthetic Joint Infection
Sites: Hamilton, Canada
- Prevention of Arrhythmia Device Infection Trial (PADIT)Pivotal-lookingCompleted
Population Health Research InstituteAcademic, hospital or other
NCT01628666 · 12,814 participants · Start Dec 2012 · Primary completion Sep 8, 2017
Drug: Incremental; Conventional · For: Arrhythmia
Sites: Hamilton, Canada
- Staphylococcus Aureus Network Adaptive Platform TrialPivotal-lookingRecruiting
University of MelbourneAcademic, hospital or other
NCT05137119 · 8,000 participants (planned) · Start Feb 16, 2022 · Primary completion Dec 1, 2028
Drug: Cefazolin; Penicillin and 2 more · For: Staphylococcus Aureus Bacteremia
Sites: Houston, Texas; Garran, Australia; Blacktown, Australia · 161 sites in all
- Prevention of Infections in Cardiac SurgeryPivotal-lookingTerminated
Hamilton Health Sciences CorporationAcademic, hospital or other
NCT02285140 · 5,989 participants · Start Apr 2015 · Primary completion Mar 10, 2025
Drug: Cefazolin; Vancomycin · For: Thoracic Surgery; Antibiotic Prophylaxis
Sites: Hamilton, Canada; Toronto, Canada; Montreal, Canada · 4 sites in all
- Prevention of Infections in Cardiac Surgery (PICS) Prevena StudyPivotal-lookingCompleted
Population Health Research InstituteAcademic, hospital or other
NCT03402945 · 4,107 participants · Start Mar 5, 2018 · Primary completion Apr 27, 2023
Drug: Cefazolin; Vancomycin · For: Surgical Site Infections
Sites: Hamilton, Canada; London, Canada
- Simplified Selective Digestive Tract Decontamination for the Prevention of Intensive Care Unit Acquired InfectionsPivotal-lookingStatus unknown
Rambam Health Care CampusAcademic, hospital or other
NCT01798537 · 2,400 participants (planned) · Start Jun 2013 · Primary completion Jul 2015
Drug: Neomycin Colistin Nystatin Vancomycin · For: Bacteremia Associated With Intravascular Line; Ventilator Associated Pneumonia; Bacteremia
Sites: Haifa, Israel
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective874
- acute kidney injury582
- off label use519
- pyrexia482
- rash345
- drug reaction with eosinophilia and systemic symptoms317
- pneumonia310
- sepsis310
- drug hypersensitivity305
- diarrhoea296
- condition aggravated283
- hypotension258
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 61 |
| 2005 | 51 |
| 2006 | 92 |
| 2007 | 150 |
| 2008 | 271 |
| 2009 | 101 |
| 2010 | 92 |
| 2011 | 108 |
| 2012 | 167 |
| 2013 | 236 |
| 2014 | 217 |
| 2015 | 320 |
| 2016 | 230 |
| 2017 | 244 |
| 2018 | 361 |
| 2019 | 468 |
| 2020 | 524 |
| 2021 | 682 |
| 2022 | 964 |
| 2023 | 959 |
| 2024 | 818 |
| 2025 | 699 |
| 2026 | 396 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Fidaxomicin versus vancomycin for Clostridium difficile infection.
Louie TJ, Miller MA, Mullane KM, et al. · N Engl J Med 2011 · Clinical Trial, Phase III, Comparative Study
- Epidemiology and outcomes of vancomycin-resistant enterococcus infections: a systematic review and meta-analysis.
Eichel VM, Last K, Brühwasser C, et al. · J Hosp Infect 2023 · Meta-Analysis, Systematic Review
- Meta-analysis of vancomycin versus linezolid in pneumonia with proven methicillin-resistant Staphylococcus aureus.
Kato H, Hagihara M, Asai N, et al. · J Glob Antimicrob Resist 2021 · Meta-Analysis, Systematic Review
- Risk factors for vancomycin-associated acute kidney injury: A systematic review and meta-analysis.
Kim JY, Yee J, Yoon HY, et al. · Br J Clin Pharmacol 2022 · Meta-Analysis, Systematic Review
- Comparative effectiveness of daptomycin versus vancomycin among patients with methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections: A systematic literature review and meta-analysis.
Adamu Y, Puig-Asensio M, Dabo B, et al. · PLoS One 2024 · Comparative Study, Meta-Analysis
- Fecal Microbiota Transplantation Versus Vancomycin for Primary Clostridioides difficile Infection : A Randomized Controlled Trial.
Juul FE, Bretthauer M, Johnsen PH, et al. · Ann Intern Med 2025 · Equivalence Trial, Multicenter Study
Sponsor: Ani Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.